Related Experiment Video

Updated: May 21, 2026

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
07:08

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species

Published on: February 27, 2018

The pathophysiology and pharmacological treatment of Huntington disease

Connie Pidgeon1, Hugh Rickards

  • 1Michael Trimble Neuropsychiatry Research Group, Department of Neuropsychiatry, BSMHFT and University of Birmingham, Birmingham, UK. CHP874@bham.ac.uk

Behavioural Neurology
|June 21, 2012
PubMed

Insights

Current Huntington disease (HD) treatments offer limited symptomatic relief. Tetrabenazine effectively manages chorea, but evidence for other pharmacotherapies, especially for non-motor symptoms, remains poor, necessitating further research.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Genetics

Background:

  • Huntington disease (HD) is a progressive, autosomal dominant neurodegenerative disorder.
  • HD presents with motor, cognitive, and behavioral impairments.
  • Current treatments focus on symptomatic relief, not disease modification.

Purpose of the Study:

  • To systematically review the evidence for pharmacological treatments of motor and non-motor symptoms in Huntington disease.
  • To identify effective pharmacotherapies for Huntington disease symptom management.

Main Methods:

  • Systematic literature review across five major scientific databases.
  • Inclusion of 23 original studies.
  • Analysis of various drug classes including dopamine depleting agents, neuroleptics, and others.

Main Results:

  • Tetrabenazine (TBZ), a dopamine-depleting agent, was the only drug with statistically significant efficacy for chorea.
  • Most studies focused on motor symptom treatment.
  • Limited evidence exists for other drug classes and non-motor symptoms.

Conclusions:

  • The evidence base for pharmacological management of Huntington disease is currently weak.
  • High-quality randomized controlled trials are needed, particularly for non-motor symptoms.
  • Further research is crucial for developing effective HD pharmacotherapies.
Abstract

More Related Videos

Efficient and Scalable Production of Full-length Human Huntingtin Variants in Mammalian Cells using a Transient Expression System10:52

Efficient and Scalable Production of Full-length Human Huntingtin Variants in Mammalian Cells using a Transient Expression System

Published on: December 10, 2021

Ole Isacson: Development of New Therapies for Parkinson's Disease23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

Related Concept Videos

Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...